Form D · Biotechnology
ME THERAPEUTICS HOLDINGS INC.
Vancouver, A1 · CIK 0001990555
Offering snapshot reported Aug 29, 2023 · SEC filing
- Reported sold
- $3.35K Offering amount: $3.35K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 9, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 29, 2023 | Initial | $3,350 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-490912
CDN$4,500 based on Bank of Canada exchange rate of $0.7445 on August 9, 2023.
Source: Form D, filed Aug 29, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Salim Dhanji | Director, Executive |
| Kenneth Harder | Director |
| Jamil Kassam | Executive |
| Quinn Martin | Executive |
| Karim Nanji | Director |
| John Priatel | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
177 Robson Street
Vancouver, A1, V6B 0N3
Vancouver, A1, V6B 0N3